Dottorato in Medicina Molecolare

1. Chegaev K, Riganti C, Lazzarato L, Rolando B, Guglielmo S, Campia I, Fruttero R, Bosia A, Gasco A. Nitric oxide donor – doxorubicin conjugates accumulate into doxorubicin resistant human colon cancer cells inducing cytotoxicity. ACS Med Chem Lett 2011, dx.doi.org/10.1021/ml100302t

2. Riganti C, Campia I, Kopecka J, Gazzano E, Doublier S, Aldieri E, Bosia A, Ghigo D. Pleiotropic effects of cardioactive glycosides. Curr Med Chem. 2011;18(6):872-85.

3. Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A, Riganti C. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Control Release. 2011; 149(2):196-205.

 4. Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D, Bosia A, Riganti C. Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med. 2010; [Epub ahead of print]

5.  Campia I, Lussiana C, Pescarmona G, Ghigo D, Bosia A, Riganti C. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. Br J Pharmacol. 2009; 158(7):1777-86.

6.  Riganti C, Campia I, Polimeni M, Pescarmona G, Ghigo D, Bosia A. Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells. Toxicol Appl Pharmacol. 2009; 240(3):385-92.

 7.  Campia I, Gazzano E, Pescarmona G, Ghigo D, Bosia A, Riganti C. Digoxin and ouabain increase the synthesis of cholesterol in human liver cells. Cell Mol Life Sci. 2009; 66(9):1580-94.

 8.  Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I, Ghigo D. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab. 2008; 9(8): 686-96.

-2010:

Campia I, Kopecka J, De Boo S, Brusa D, Matera L, Ghigo D,  Bosia A and Riganti C “iNos activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells”, Annual Reunion of Italian Biochemestry Society, Section “Ligure- Lombardo –Piemontese” (SIB/LLP), Varese, Italy, 28 May 2010 (oral communication)

- Campia I,  Riganti C, Voena C, Kopecka J, Enrico E, Costamagna C, Ghigo D and Bosia A,  “Liposomal doxorubicin reverses drug-resistance by inhibiting P-glycoprotein in human cancer cells”, 23^rd Annual Congress of Italian Society of  Cell Culture (AICC) on “Nanotechnologies and Drug Delivery”,Milan,Italy, 24-26 November 2010   (poster and oral communication)

-2011:

- Campia I,  Riganti C, Castella B, Kopecka J, Massaia M,  Ghigo D and Bosia A, “Zoledronic acid modulates multidrug resistance and immunogenic cell death in human cancer cells”,“5th Cervo Preclinical Working Conference 2011”, Cervo Ligure, 7 Ottobre 2011 (oral communication)

-2012:

- Campia I, Kopecka J, Pescarmona GP, Ghigo D , Bosia, A and Riganti C, Cardioactive glycosides induce the efflux of cholesterol by upregulating ABCA1,"4th FEBS Special Meeting on ABC Proteins", Innsbruck, 3-9 Marzo 2012 (poster presentation)

- “Convegno annuale SIB/LLP” , sezione ligure-lombardo-piemontese della Società Italiana di Biochimica e Biologia Molecolare (SIB), Novara, 20 Maggio 2011

- “The Biology of Cancer Oncogene and Microenvironment”, Fondazione Piemontese per la Ricerca sul Cancro-ONLUS, Torino 29 Maggio 2011

- “Doxorubicina liposomiale pegilata (pld) nel carcinoma epiteliale dell’ovaio:stato dell’arte e prospettive future”, Molecular Biotechnology Center, Torino 17 Giugno 2011

- “36th FEBS Congress- Biochemistry for Tomorrow’s Medicine”, Torino, 25-30 Giugno 2011

- "5th Cervo Preclinical Working Conference 2011", Cervo Ligure, 6-8 Ottobre 2011

- "4th FEBS Special Meeting on ABC Proteins", Innsbruck, 3-9 Marzo 2012

- “Novel nanoparticles capturing low abundance biological peptides: application for cancer biomarker discovery”, Dott.ssa Claudia Fredolini, 24 Gennaio 2011

 -“BLIMP2 is a tumor suppressor gene frequently  in activate B cell-like diffuse large B cell lymphoma”, Prof.  Riccardo dalla Favera,  7 Febbraio 2011

 -“The escape of  cancer from immune surveillance: MHC expression and tumor rejection”, Prof. Federico Garrido, 21 Marzo 2011

 -"Senescence and cancer", Prof. Daniel S. Peeper, 15 Aprile 2011

-"Manipulation of senescence pathways for  cancer therapy: from experimental model to clinic", Prof. Andrea Alimonti, 19 Aprile 2011

-“Primary cells, cell culture and mycoplasma prevention”, PBInternational, Molecular Biotechnology Center, Torino  21 Giugno 2011

-"D-Day" Scuola di Dottorato in Scienze della Vita e della Salute, 19 settembre 2011

-“La ricerca?... Che impresa!” Opportunità  e percorsi per valorizzare la Ricerca e favorire il Trasferimento Tecnologico, 29 Settembre 2011

- “FEBS Practical Course on Protein Interaction Modules”, Spalato, Croazia, 2-9 Settembre 2011